$86 Million

X4 Pharmaceuticals, Inc.

Follow-on Offering

Lead Left Bookrunner, April 2019

X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and cancer.